ASAHI INTECC (7747) FY2026 Q2 Earnings Report

Quick View

Executive Summary

This was an earnings result featuring both revenue and profit growth, accompanied by a notable improvement in profit margins; the qualitative enhancement of the earnings structure is the key takeaway. Revenue was ¥712.7B (+15.9% YoY), Operating Income was ¥243.7B (+40.1%), Ordinary Income was ¥241.4B (+43.5%), and Net Income was ¥172.5B (+40.3%). The Operating Income margin was 34.2%, improving by approximately 6 points from 28.3% in the same period of the previous year. The primary driver of profit growth was the realization of operating leverage, underpinned by the high gross margin of 70.6%; segment profit margins improved in both the Medical Business and Device Business.

Factors Affecting Business Performance

【Revenue】Revenue increased 15.9% YoY to ¥712.7B. By segment, the Medical Business recorded ¥626.6B (88.0% of total, +12.4% YoY), while the Device Business recorded ¥169.2B (+50.2%), demonstrating a high growth rate.

【Profit and Loss】Operating Income increased 40.1% YoY to ¥243.7B, while Ordinary Income increased 43.5% to ¥241.4B, with profit growth substantially exceeding revenue growth. Against the backdrop of a 70.6% gross margin (improving from approximately 66.7% in the previous year), the Company achieved profit growth substantially exceeding the 7.4% increase in SG&A expenses. In non-operating items, a foreign exchange loss of ¥3.2B was recorded, resulting in a non-operating loss of ¥2.3B; however, a gain on the sale of investment securities of ¥6.3B was recorded as extraordinary income, bringing Profit Before Tax to ¥247.7B. Net Income was ¥172.5B (+40.3%), and the contribution from extraordinary income was limited to approximately 2.5% of Profit Before Tax, indicating that the majority of profit growth resulted from improved core earnings power. In conclusion, the Company achieved both revenue and profit growth, with the structural improvement in profit margins—as indicated by the profit growth rate exceeding the revenue growth rate—being a notable feature.

Segment Analysis

The Medical Business recorded sales to external customers of ¥626.7B (+12.4% YoY) and segment profit of ¥239.5B (+29.3%), with its profit margin improving to 38.2% from 33.2% in the same period of the previous year, an improvement of approximately 5 points. It made the largest contribution to consolidated Operating Income and is positioned as the core business. The Device Business recorded revenue of ¥169.2B (including intersegment internal sales, +30.0% YoY) and segment profit of ¥43.9B (+78.8%), demonstrating high growth that exceeded the Medical Business in both revenue and profit growth rates. However, its profit margin was 26.0%, lower than that of the Medical Business, and the growth mix of the two businesses may affect the consolidated profit margin going forward. Corporate expenses (adjustments) increased to ¥39.7B from ¥35.8B in the previous year, but the profit growth of both segments absorbed the increase.

Key Financial Metrics

【Profitability】The Operating Income margin of 34.2% and Net Income margin of 24.2% both improved significantly from the same period of the previous year, while the high-value-added earnings structure, reflected in the 70.6% gross margin, is generating operating leverage. ROE was 10.9%. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥177.8B, exceeding Net Income of ¥172.5B, and OCF/Net Income was approximately 1.03x, indicating sound cash backing for earnings. 【Investment Efficiency】Capital expenditures were ¥23.7B, compared with depreciation and amortization expenses of ¥44.6B; CapEx/depreciation and amortization remained at approximately 0.53x, indicating that replacement and capacity-enhancement investments were at a restrained level. 【Financial Soundness】The Equity Ratio was high at 81.0%; current assets of ¥1045.6B substantially exceeded current liabilities of ¥223.6B, and interest-bearing debt was also limited, indicating an extremely solid financial foundation.

Cash Flow Analysis

Operating Cash Flow was ¥177.8B, almost unchanged at -2.7% YoY, and exceeded Net Income of ¥172.5B, indicating sound cash backing for earnings. Meanwhile, an increase in inventories of ¥12.1B and a decrease in advances received of ¥6.1B (IncreaseDecreaseInAdvancesReceived) absorbed cash through working capital, causing cash conversion efficiency relative to EBITDA to decline slightly from the previous year. Investing Cash Flow was negative ¥9.6B, as proceeds from the sale of investment securities and other recoveries partially offset capital expenditures of ¥23.7B. Financing Cash Flow was negative ¥185.9B, with share repurchases of ¥105.5B and dividend payments of ¥65.3B being the primary sources of outflow. Free Cash Flow was ¥168.3B, a level sufficient to almost cover shareholder returns combining share repurchases and dividends even after capital expenditures, while cash and deposits remained ample at ¥535.0B.

Quality of Earnings

Against Ordinary Income of ¥241.4B, non-operating income and expenses, including the ¥3.2B foreign exchange loss, amounted to negative ¥2.3B and reduced earnings; meanwhile, a gain on the sale of investment securities of ¥6.3B was recorded as extraordinary income, resulting in Profit Before Tax of ¥247.7B. This temporary factor represented approximately 2.5% of Profit Before Tax, and its impact on Net Income was limited; therefore, the majority of profit growth can be judged to have resulted from improved core earnings power. Comprehensive Income was ¥243.8B, exceeding Net Income of ¥172.5B; the difference was primarily attributable to foreign currency translation adjustments of ¥69.4B, reflecting an increase in the yen-translated valuation of overseas assets. The fact that OCF exceeded Net Income supports the quality of earnings from an accrual perspective; however, working capital movements in inventories and advances received slightly constrained cash generation. Accordingly, while the quality of earnings is generally sound, continued monitoring of working capital trends would be useful.

Earnings Forecast and Guidance

Progress against the full-year forecast was 50.5% for Revenue, 57.7% for Operating Income, and 56.6% for Ordinary Income, representing a pace above the standard first-half progress rate of 50%. The full-year forecast calls for Revenue of ¥1411.4B (+17.6% YoY) and Operating Income of ¥422.2B (+40.4%), a plan broadly consistent with the high growth rates achieved in the first half. However, the second-half Operating Income margin implied by the full-year forecast is approximately 25.5%, below the first-half result of 34.2%; the plan can therefore be viewed as assuming normalization of margins in the second half. The revision of the earnings forecast and dividend forecast during the quarter is also noteworthy as a move reflecting the rapid pace of progress.

Shareholder Returns

The Q2-end dividend was ¥0 per share, reflecting a policy of concentrating dividends at the fiscal year-end. The full-year dividend forecast is ¥46.10 per share, comprising an ordinary dividend of ¥40.31 and a commemorative dividend of ¥5.79. The Payout Ratio against full-year forecast EPS of ¥114.88 is approximately 40.1%. Separately, the Company conducted share repurchases of ¥105.5B. Shareholder returns combining dividends and share repurchases are high relative to Net Income of ¥172.5B; however, they should be evaluated separately from the Payout Ratio. OCF of ¥177.8B exceeded dividend payments of ¥65.3B on a cash flow basis, providing sufficient support for the source of shareholder returns.

Risk Factors

1. Working capital efficiency: Inventories were ¥91.7B (an inventory composition including ¥102.0B of work-in-process), showing an increasing trend from the previous year. The ¥12.1B increase in inventories and decrease in advances received are constraining cash conversion. Even taking into account the production and supply lead times characteristic of medical device manufacturing, working capital efficiency remains an area requiring ongoing monitoring.

2. Foreign exchange fluctuations: A foreign exchange loss of ¥3.2B was recorded in non-operating expenses, weighing on overall non-operating income and expenses. Given the business structure involving overseas sales and procurement, foreign exchange fluctuations may become a factor affecting Ordinary Income.

3. Profitability gap between segments: While the Device Business recorded a substantial increase in revenue YoY, its 26.0% profit margin was below the Medical Business’s 38.2%. If growth in the Device Business increases its share of the consolidated revenue mix, changes in the product mix may affect the consolidated profit margin.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Both the Operating Income margin and Net Income margin substantially exceed the industry median, positioning the Company among the industry’s high-profitability group.

Growth and Capital Efficiency

The Revenue growth rate exceeds the industry median but remains below the upper range of the industry (25.4%).

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Operating Income growth of +40.1%, exceeding Revenue growth of +15.9%, demonstrates the realization of operating leverage against the backdrop of a 70.6% gross margin. The structure of profit growth exceeding revenue growth is the central feature of these earnings results.

2. The 57.7% progress rate for Operating Income against the full-year forecast is solid. However, the full-year plan incorporates a decline in the second-half Operating Income margin to approximately 25.5% from the first-half result of 34.2%, making the margin trend in the second half a key area of focus going forward.

3. Capital expenditures of ¥23.7B were limited to approximately 0.53x depreciation and amortization expenses of ¥44.6B. While abundant Free Cash Flow of ¥168.3B is being allocated to shareholder returns, the level of investment related to production capacity and quality remains an area requiring continued monitoring.

Theoretical Share Price (Reference Value)

Sensitivity: ¥787–¥834 at ±1% for the cost of equity, and ¥804–¥818 at ±0.1 for ω.

Notes:

• Goodwill amortization of ¥0.4 per share has been added back to earnings (as a non-cash expense and for comparability with IFRS companies).
• Net assets as of the quarter-end have been used (there is a timing gap relative to the full-year forecast).
• Since net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q2 was a very strong earnings release, with revenue growth translating into substantial margin expansion and a stronger-than-forecast first-half operating-profit outcome. Revenue rose 15.9% YoY to ¥71.27bn. Operating income increased 40.1% to ¥24.37bn, materially outpacing sales growth. Ordinary income grew 43.5% to ¥24.14bn. Net income attributable to owners increased 40.4% to ¥17.21bn, and EPS was ¥64.56. Gross margin improved to 70.6% from 67.6% a year earlier, an expansion of approximately 300bp. Operating margin rose to 34.2% from 28.3%, an expansion of approximately 590bp. Net margin increased to 24.1% from 19.9%, or approximately 430bp. The margin gain reflects high operating leverage, as SG&A rose only 7.2% YoY, well below 15.9% revenue growth. Medical remained the core earnings business, contributing ¥23.95bn of segment profit, while Device delivered substantially faster growth. Cash earnings were broadly supported, with operating cash flow of ¥17.78bn equaling 1.03x net income and an accruals ratio of negative 0.3%. However, OCF/EBITDA was only 0.62x, indicating that EBITDA-to-cash conversion was held back by operating cash-flow uses despite solid net-income conversion. The balance sheet remains exceptionally conservative, supported by ¥53.50bn of cash, a 467.6% current ratio, and only 0.27x debt/EBITDA. Free cash flow was ¥16.83bn during the first half, but the ¥10.55bn share repurchase resulted in a capital return burden that exceeded first-half earnings when combined with the planned full-year dividend. Management's full-year forecast calls for ¥141.14bn in revenue and ¥42.22bn in operating income; first-half progress of 50.5% for revenue and 57.7% for operating income indicates a profit-weighted first half and supports the revised outlook. The principal operational items to monitor are elevated inventory-cycle metrics and CapEx running below depreciation, particularly given the company's manufacturing and medical-device growth profile.

Profitability Analysis

Annualized DuPont ROE is 21.7%, comprising a 24.1% net profit margin, 0.728x annualized asset turnover, and 1.23x financial leverage. The principal driver of the high return profile is profitability rather than leverage: leverage is low and conservative, while the net margin is exceptionally high. EBIT margin was 34.2%, matching operating margin, and EBITDA margin was 40.5%, underscoring strong gross-profit generation and a relatively limited fixed-cost burden at the consolidated level. Gross margin expanded approximately 300bp YoY to 70.6%, while operating margin expanded approximately 590bp, showing that the gross-profit improvement was amplified by operating leverage. SG&A increased to ¥25.94bn from ¥24.15bn, a 7.2% increase versus 15.9% sales growth, which is the clearest evidence of positive cost leverage. The five-factor DuPont tax burden was 0.695 and the interest burden was 1.016; the latter reflects immaterial financing costs and non-operating income exceeding interest expense. Interest expense was only ¥0.78bn against EBIT of ¥24.37bn, producing 312.46x interest coverage. Under JGAAP, goodwill amortization was ¥0.57bn, but this was only about 0.2% of EBITDA; EBITDA before goodwill amortization was ¥28.89bn, so JGAAP goodwill accounting does not materially distort comparability. The ¥6.29bn gain on sale of securities lifted pre-tax profit above ordinary income; this gain equals 3.7% of net income and should be separated from recurring operating performance. Excluding that securities gain, underlying profitability remains strong because operating income itself rose 40.1% YoY.

Growth Assessment

Growth was broad-based across both reported segments. Medical external revenue increased 12.4% YoY to ¥62.67bn, while segment profit rose 29.3% to ¥23.95bn. Medical segment margin on total segment sales improved to 38.2% from 33.2%, confirming strong incremental profitability in the core business. Device external revenue increased 50.2% YoY to ¥8.60bn. Device total segment sales, including intersegment sales, rose 30.0% to ¥16.92bn, while segment profit surged 78.8% to ¥4.39bn. Device segment margin on total segment sales improved to 26.0% from 18.9%, indicating meaningful scale benefits. The Medical business is the core business by operating-income contribution, accounting for approximately 84.5% of combined segment profit before corporate-cost adjustment. Consolidated operating income rose faster than segment profit because the corporate-cost adjustment widened only modestly to negative ¥3.97bn from negative ¥3.58bn. The full-year forecast implies second-half revenue of ¥69.88bn and operating income of ¥17.85bn. First-half revenue progress is 50.5%, essentially in line with the standard 50% Q2 benchmark. Operating-income progress is 57.7%, 7.7 percentage points above the standard benchmark, while net-income progress is 56.3% based on forecast EPS. This profile suggests management expects some normalization in second-half profitability, but it does not signal an unusually large deviation from normal first-half progress. The full-year plan calls for 17.6% sales growth and 40.4% operating-income growth, requiring continued margin preservation as growth continues.

Financial Health

Financial health is very strong. Current assets of ¥104.56bn exceeded current liabilities of ¥22.36bn by ¥82.20bn, producing working capital of ¥82.20bn and a current ratio of 467.6%. The quick ratio was also exceptionally high at 426.6%, as liquidity is primarily cash-based rather than dependent on inventory realization. Cash and deposits of ¥53.50bn were 22.47x short-term loans of ¥2.38bn. Interest-bearing debt totaled ¥7.83bn, equivalent to only 0.23x equity, 0.27x EBITDA, and 4.7% of total capital. Long-term loans were ¥5.45bn and short-term loans were ¥2.38bn; the 30.4% short-term-debt ratio is readily covered by cash and current assets, so there is no apparent maturity mismatch risk. Total liabilities represented only 19.0% of total assets, while owners' equity was ¥157.78bn. The equity ratio improved to 80.6% from 77.9% a year earlier, aided by accumulated profitability and OCI gains. Foreign-currency translation adjustment increased to ¥211.92bn, contributing to accumulated OCI of ¥234.88bn and making reported equity partly sensitive to future currency translation movements. Treasury stock moved from negative ¥4.45bn to negative ¥0.18bn, a ¥4.44bn reduction in the contra-equity balance; together with ¥10.55bn of repurchases and the decline in capital surplus, this is consistent with active capital-structure management including repurchase execution and likely share retirement. Goodwill declined from ¥1.10bn to ¥0.60bn, down 45.5%; at 0.0% of equity and 0.00x EBITDA, there is no meaningful goodwill impairment dependence. Asset retirement obligations were ¥2.00bn, equivalent to approximately 0.5% of liabilities, which is modest.

Notable B/S Changes

Treasury stock: ¥(4.45)bn to ¥(0.18)bn, a ¥4.44bn reduction in the contra-equity balance (+99.6%) - reflects significant capital-structure activity alongside ¥10.55bn of first-half share repurchases and should be assessed with ongoing return policy. Goodwill: ¥1.10bn to ¥0.60bn, down ¥0.50bn (-45.5%) - the remaining balance is immaterial at 0.0% of equity and 0.00x EBITDA, limiting goodwill impairment risk. Property, plant and equipment: ¥590.82bn to ¥608.76bn, up ¥17.94bn (+3.0%) - PPE remains substantial at 31.1% of total assets, while first-half CapEx below depreciation should be monitored for future capacity and replacement needs. Foreign-currency translation adjustment: ¥143.15bn to ¥211.92bn, up ¥68.77bn (+48.0%) - a major contributor to the increase in equity and comprehensive income, but also a source of potential book-value volatility.

Cash Flow Quality

First-half operating cash flow was ¥17.78bn, equivalent to 1.03x net income attributable to owners of ¥17.21bn. This exceeds the 0.8x quality threshold and supports the quality of reported earnings. The negative 0.3% accruals ratio also indicates low accrual-driven earnings risk. Free cash flow was ¥16.83bn after ¥2.37bn of capital expenditures, providing substantial internal funding capacity. Cash conversion measured as OCF/EBITDA was nonetheless 0.62x, below the 0.7x warning threshold. The root cause is that the cash-flow statement includes material operating cash uses, notably a ¥6.06bn reduction in advances received and a ¥1.21bn inventory increase, alongside tax payments. The impact is not a near-term liquidity concern because cash reserves and free cash flow remain substantial, but it warrants monitoring as sustained working-capital absorption would reduce the cash yield of EBITDA. The quality alert for inventory days of 231 days is material: on the broader manufacturing inventory base of raw materials, work in process, and finished goods, inventory is elevated relative to production cost and ties up cash in the operating cycle. Work in process of ¥10.20bn is the largest disclosed manufacturing inventory category, ahead of finished goods of ¥9.17bn and raw materials of ¥7.11bn, which points to an in-process production-cycle concentration. The 250-day annualized cash conversion cycle alert similarly indicates a long cash commitment from procurement and production through collection. These conditions can be partly consistent with specialized medical-device manufacturing, qualification requirements, and supply assurance, but they increase exposure to demand-forecast errors, production bottlenecks, and inventory obsolescence. A separate 80-day inventory-days alert uses a narrower reported inventory scope; although less severe than the broader 231-day measure, it remains above the 60-day manufacturing benchmark and confirms that inventory efficiency merits attention. CapEx was ¥2.37bn, equal to 0.53x depreciation and amortization of ¥4.46bn. The underinvestment and CapEx-underinvestment alerts therefore have the same root cause: replacement and expansion investment is currently below the depreciation charge. This supports near-term free cash flow, but if sustained, it could constrain capacity, automation, process improvement, and replacement investment in a growing medical-device manufacturer.

Dividend Sustainability

No interim dividend was paid at Q2. The full-year dividend forecast is ¥46.10 per share, comprising an ordinary dividend of ¥40.31 and a commemorative dividend of ¥5.79. Based on forecast EPS of ¥114.88, the forecast dividend payout ratio is approximately 40.1%, which is within a sustainable range on an earnings basis. The ordinary-dividend component alone represents approximately 35.1% of forecast EPS, indicating that the commemorative portion is not the core recurring distribution commitment. First-half free cash flow of ¥16.83bn exceeds the implied full-year cash dividend requirement of roughly ¥12.23bn based on 265.3 million issued shares. Therefore, dividend coverage is strong even before considering the large cash balance. Capital returns should be assessed using total return ratio because the company repurchased ¥10.55bn of shares during the first half. Combining the implied full-year dividend with first-half repurchases produces a total-return amount of approximately ¥22.78bn, or about 101% of first-half net income. That total return ratio is elevated and would not be sustainable if repeated at the same pace without continued earnings and cash-flow growth. However, the balance sheet has ample capacity to accommodate the repurchase, and net debt is negative when cash is offset against borrowings. The key policy question is whether buybacks remain opportunistic or become a recurring capital-allocation commitment alongside dividends and manufacturing investment.

Risk Assessment

Business risks include Inventory and production-cycle risk is the highest operational concern: the 231-day broader inventory-days alert and 250-day annualized cash conversion cycle indicate a long cash commitment in raw materials, work in process, and finished goods., Medical is the core earnings driver, contributing approximately 84.5% of combined segment profit before corporate costs; a slowdown in procedure volumes, reimbursement pressure, regulatory requirements, customer concentration, or product-quality issues would have an outsized impact., Device growth is rapid, with external revenue up 50.2% and segment profit up 78.8%; sustaining this growth requires successful capacity planning, yields, quality control, and customer-demand conversion., Foreign-exchange exposure remains relevant for an international medical-device manufacturer. FX losses were ¥3.19bn in non-operating expenses, although they represented only about 13.1% of operating income and were materially lower than the prior-year ¥7.84bn loss., The ¥6.29bn securities-sale gain is non-recurring and should not be extrapolated into recurring ordinary operating earnings..

Financial risks include Cash conversion of 0.62x OCF/EBITDA is below the 0.7x threshold. While OCF/net income is sound at 1.03x, sustained working-capital demands could reduce free-cash-flow conversion., CapEx/depreciation of 0.53x is below the 0.7x warning threshold. Continued underinvestment could eventually create capacity, maintenance, automation, or competitive-investment risk., First-half share repurchases of ¥10.55bn increase capital returns materially; combined with the planned dividend, the implied total return ratio is approximately 101% of first-half earnings., Accumulated foreign-currency translation adjustment of ¥211.92bn is a large component of reported equity and could create OCI and book-value volatility if exchange rates reverse..

Key concerns include Priority 1: monitor inventory normalization, work-in-process conversion, and the annualized cash conversion cycle because these most directly affect cash generation and manufacturing execution., Priority 2: monitor whether CapEx rises toward at least depreciation coverage as sales and Device production scale., Priority 3: assess the durability of operating-margin expansion after separating the non-recurring securities gain from pre-tax earnings., Priority 4: track the pace and rationale of future repurchases relative to free cash flow, dividends, and growth investment..

Investment Implications

Key takeaways include Revenue growth of 15.9% translated into 40.1% operating-income growth, with operating margin expanding approximately 590bp to 34.2%., The core Medical segment retained high profitability, while Device delivered faster revenue growth and stronger segment-margin expansion., Annualized ROE of 21.7% is driven primarily by exceptional margins rather than financial leverage., Liquidity and solvency are exceptional: ¥53.50bn cash, 467.6% current ratio, 0.27x debt/EBITDA, and 312.46x interest coverage., Operating cash flow covered net income, but the 0.62x OCF/EBITDA ratio and long inventory cycle require attention., The planned ¥46.10 full-year DPS is earnings- and free-cash-flow-covered, whereas the combined dividend-plus-buyback total return burden is elevated..

Metrics to watch include Operating margin and gross margin relative to the 34.2% and 70.6% first-half levels, Medical segment revenue growth and segment margin, Device external revenue growth, total segment margin, and production scalability, Inventory days, work-in-process balance, and annualized cash conversion cycle, OCF/EBITDA cash conversion and free cash flow after tax and working-capital movements, CapEx/depreciation relative to the current 0.53x, Repurchase pace and total return ratio, FX gains/losses and foreign-currency translation movements.

Regarding relative positioning, The company exhibits a premium financial profile for a manufacturing-led medical-device group: operating margin of 34.2%, EBITDA margin of 40.5%, annualized ROE of 21.7%, and very low balance-sheet leverage. Its main relative constraint is not funding capacity but operational cash efficiency, as long inventory-cycle metrics and CapEx below depreciation contrast with otherwise strong earnings and liquidity.